Core Insights - Tevogen is advancing the development of TVGN 489, a precision T-cell therapy aimed at addressing Long COVID, coinciding with International Long COVID Awareness Month [1][4] Group 1: Company Developments - Following a new leadership appointment on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to progress TVGN 489 into the next clinical phase [2] - The company is evaluating the acquisition of Sciometrix and its Clinicus platform to enhance real-world monitoring for Long COVID patients [2][8] Group 2: Clinical Progress - Tevogen is prioritizing the development of TVGN 489, which targets the estimated 7% of U.S. adults suffering from Long COVID [3] - The proof-of-concept data indicates that none of the patients treated with TVGN 489 for acute infection developed Long COVID [4][6] Group 3: Market Reach and Infrastructure - The expanded HLA coverage of TVGN 489 now reaches 65% of the U.S. population, enhancing its potential patient eligibility [4][12] - The company is finalizing the infrastructure necessary for the next clinical phase based on the proof-of-concept data [12] Group 4: Technological Integration - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [7] - The platform utilizes cloud and data services from major technology providers to support therapeutic discovery [7]